Immunotherapy Based on Bispecific T-Cell Engager with hIgG1 Fc Sequence as a New Therapeutic Strategy in Multiple Myeloma

This is an immunotherapy investigation describing the development of a single-chain variable fragment (ScFv) combination of anti-CD3 ScFv and anti-CD138 ScFv, using hIgG1 Fc (hIgFc) sequence. The bispecific T-cell engager (BiTE) with the addition of single-chain fragment hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells. Bio-Layer Interferometry was used to determine dissociation constant (KD) of aCD138-ScFv-hIgFc and BiTE-hIgFc (STL001) antibody. A Pall ForteBio Octet RED96 instrument equipped with Streptavidin Biosensor probes was used in the kinetic characterization. The biotinylated rCD138 antigen was immobilized on to Streptavidin probes.

Read More